ClinicalTrials.gg
CompletedNCT01840410Updated Aug 26, 2016Results posted

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

A Phase 3 interventional study of Ranibizumab and Sham control in Choroidal Neovascularization (CNV), sponsored by Novartis Pharmaceuticals. Completed at 59 sites in 21 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
14th of 45
183 · median 62
Started
2013
with 5 others
Phase 3
11 of 45
none open now
Registered
33rd of 45
by date
Lead sponsor
9 of 45
Novartis Pharmaceuticals

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 14th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 33rd registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).

03

Conditions studied

  • Choroidal Neovascularization (CNV)

Keywords

  • Vision Impairment
  • Abnormal growth of blood vessels
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of active CNV secondary to any causes with the CNV or its sequelae affecting the fovea;
  • BCVA must be between ≥ 24 and ≤ 83 letters in the study eye;
  • Visual loss in the study eye should mainly be due to the presence of any eligible types of CNV;

Key Exclusion Criteria:

  • Women of ;
  • Active ;
  • History of stroke less than 6 months prior to screening;
  • Uncontrolled systemic inflammation or infection;
  • Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;
  • CNV- conditions with a high likelihood of spontaneous resolution;
  • History of intravitreal treatment with ;
  • History of laser photocoagulation;
  • History of intraocular treatment with any anti-angiogenic drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.

    Drug: Ranibizumab

  • Sham comparator
    Sham control

    Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

    Other: Sham control

Interventions

  • Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.

  • OtherSham control

    The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using mixed model repeated measures (MMRM) which contained scheduled visit, the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate and treatment group by visit and visit by centered baseline BCVA interactions. A positive change from baseline indicated improvement.

    Time frame: Baseline, Month 2

Secondary outcomes

  1. Change From Baseline in BCVA in Study Eye up to Month 2

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using analysis of covariance (ANCOVA) model which contained the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate. A positive change from baseline indicated improvement.

    Time frame: Baseline, Month 1, Month 2

  2. Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye

    CSFT was assessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  3. Change From Baseline in Central Subfield Volume (CSFV) in Study Eye

    CSFV was assessed OCT. A negative change from baseline indicates improvement.

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  4. Number of Participants With Presence of Intra-retinal Fluid in Study Eye Compared to Baseline

    The presence of intra-retinal fluid was assessed by OCT.

    Time frame: Baseline, Month 2, Month 6, Month 12

  5. Number of Participants With Presence of Subretinal Fluid in Study Eye Compared to Baseline

    Presence of subretinal fluid in study eye compared to baseline

    Time frame: Baseline, Month 2, Month 6, Month 12

  6. Number of Participants With Presence of Active Chorioretinal Leakage

    The presence of active chorioretinal leakage was assessed by photography imaging, i.e. fluorescein angiography (FA).

    Time frame: Baseline, Month 2, Month 6, Month 12

  7. Average Change From Baseline in BCVA

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. BCVA was assessed at each month from Month 1 through Month 6 or at each month from Month 1 through month 12, and the data were averaged. The outcome measure is reporting the change between baseline and average BCVA from Month 1 through Month 6 or from Month 1 through Month 12 (average BCVA - baseline BCVA). A positive change from baseline indicated improvement.

    Time frame: Baseline (BL), Month 1 through Month 6, Month 1 through Month 12

  8. Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters

    VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Month 2, Month 6, Month 12

  9. Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss

    VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Month 2, Month 6, Month 12

  10. Number of Participants With Requirement for Rescue Treatment at Month 1

    Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.

    Time frame: Month 1

  11. Number of Participants With Ranibizumab Treatments in Study Eye

    The number of participants administered study treatments, according to treatment frequency, was assessed.

    Time frame: Month 12

  12. Number of Participants With Re-treatments

    The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to month 12, the maximum number of retreatments was 5.

    Time frame: Month 12

  13. Number of Primary Reasons for Decision to Treat by Investigator

    The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.

    Time frame: Month 12

07

Results

Posted Aug 26, 2016

Participant flow

Participant flow — Overall Study
MilestoneRanibizumabSham Control
Started11959
Safety set11959
Full analysis set11959
Completed11255
Not completed74
Withdrew: Physician decision12
Withdrew: Pregnancy10
Withdrew: Protocol deviation10
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject21
Withdrew: Adverse event11

Outcome measures

PrimaryChange From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using mixed model repeated measures (MMRM) which contained scheduled visit, the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate and treatment group by visit and visit by centered baseline BCVA interactions. A positive change from baseline indicated improvement.

Time frame:
Baseline, Month 2
Reported as:
Least squares mean · letters
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2
lettersRanibizumabSham Control
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 29.5 ± 0.95-0.4 ± 1.16
Statistical analysis
  • Ranibizumab vs Sham Control · Mixed Models Analysis · p = <0.001 · Mean difference (net): 9.94 · 95% CI 6.97 to 12.91
SecondaryChange From Baseline in BCVA in Study Eye up to Month 2

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. The data were analyzed using analysis of covariance (ANCOVA) model which contained the type of underlying pathophysiologic mechanism (angloid streaks versus others) and treatment group as fixed effect factors, centered baseline BCVA as a continuous covariate. A positive change from baseline indicated improvement.

Time frame:
Baseline, Month 1, Month 2
Reported as:
Least squares mean · letters
Change From Baseline in BCVA in Study Eye up to Month 2
lettersRanibizumabSham Control
Month 17.1 ± 0.750.1 ± 1.08
Month 29.5 ± 0.91-0.4 ± 1.31
SecondaryChange From Baseline in Central Subfield Thickness (CSFT) in Study Eye

CSFT was assessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · micrometer (um)
Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye
micrometer (um)RanibizumabSham Control
Month 1 (n=115,56)-74.4 ± 81.253.3 ± 89.43
Month 2 (n=114,54)-76.4 ± 108.241.9 ± 119.44
Month 3 (n=114,56)-82.9 ± 114.26-59.1 ± 142.37
Month 4 (n=114,56)-83.5 ± 104.71-68.4 ± 155.26
Month 5 (n=116,55)-83.8 ± 112.41-89.4 ± 130.68
Month 6 (n=112,54)-89.1 ± 109.19-85.9 ± 117.54
Month 7 (n=114,55)-83.1 ± 105.97-84.5 ± 141.36
Month 8 (n=111,55)-94.7 ± 111.54-97.9 ± 118.34
Month 9 (n=110,55)-90.0 ± 112.44-93.5 ± 113.88
Month 10 (n=108,53)-100.5 ± 119.45-85.4 ± 136.90
Month 11 (n=110,55)-99.5 ± 112.38-82.8 ± 158.78
Month 12 (n=109,55)-102.7 ± 117.27-91.7 ± 152.36
SecondaryChange From Baseline in Central Subfield Volume (CSFV) in Study Eye

CSFV was assessed OCT. A negative change from baseline indicates improvement.

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · microliter (ul)
Change From Baseline in Central Subfield Volume (CSFV) in Study Eye
microliter (ul)RanibizumabSham Control
Month 1 (n=115,56)-0.354 ± 0.41030.012 ± 0.3608
Month 2 (n=114,54)-0.357 ± 0.5480-0.006 ± 0.5792
Month 3 (n=114,56)-0.369 ± 0.5506-0.269 ± 0.6583
Month 4 (n=114,56)-0.371 ± 0.4798-0.291 ± 0.7647
Month 5 (n=116,55)-0.392 ± 0.5404-0.381 ± 0.5750
Month 6 (n=112,54)-0.409 ± 0.5305-0.375 ± 0.5310
Month 7 (n=114,54)-0.366 ± 0.4905-0.374 ± 0.5966
Month 8 (n=110,55)-0.414 ± 0.5021-0.411 ± 0.4970
Month 9 (n=110,55)-0.404 ± 0.5182-0.413 ± 0.5251
Month 10 (n=108,53)-0.437 ± 0.5506-0.385 ± 0.5688
Month 11 (n=110,55)-0.448 ± 0.5285-0.352 ± 0.7021
Month 12 (n=109,55)-0.441 ± 0.5460-0.378 ± 0.6704
SecondaryNumber of Participants With Presence of Intra-retinal Fluid in Study Eye Compared to Baseline

The presence of intra-retinal fluid was assessed by OCT.

Time frame:
Baseline, Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Presence of Intra-retinal Fluid in Study Eye Compared to Baseline
ParticipantsRanibizumabSham Control
Baseline, Absent (n=116,56)7032
Baseline, Definite (n=116,56)4624
Month 2, Absent (n=116,56)9729
Month 2, Definite (n=116,56)1927
Month 6, Absent (n=116,54)10043
Month 6, Definite (n=116,54)1611
Month 12, Absent (n=111,55)9545
Month 12, Definite (n=111,55)1610
SecondaryNumber of Participants With Presence of Subretinal Fluid in Study Eye Compared to Baseline

Presence of subretinal fluid in study eye compared to baseline

Time frame:
Baseline, Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Presence of Subretinal Fluid in Study Eye Compared to Baseline
ParticipantsRanibizumabSham Control
Baseline, Absent (n=116,56)166
Baseline, Definite (n=116,56)10050
Month 2, Absent (n=116,56)7211
Month 2, Definite (n=116,56)4445
Month 6, Absent (n=116,54)7734
Month 6, Definite (n=116,54)3920
Month 12, Absent (n=111,55)7841
Month 12, Definite (n=111,55)3314
SecondaryNumber of Participants With Presence of Active Chorioretinal Leakage

The presence of active chorioretinal leakage was assessed by photography imaging, i.e. fluorescein angiography (FA).

Time frame:
Baseline, Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Presence of Active Chorioretinal Leakage
ParticipantsRanibizumabSham Control
Baseline, Absent (n=106,50)21
Baseline, Definite (n=106,50)10449
Month 2, Absent (n=106,50)374
Month 2, Definite (n=106,50)6946
Month 6, Absent (n=108,45)6429
Month 6, Definite (n=108,45)4416
Month 12, Absent (n=103,47)8137
Month 12, Definite (n=103,47)2210
SecondaryAverage Change From Baseline in BCVA

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. BCVA was assessed at each month from Month 1 through Month 6 or at each month from Month 1 through month 12, and the data were averaged. The outcome measure is reporting the change between baseline and average BCVA from Month 1 through Month 6 or from Month 1 through Month 12 (average BCVA - baseline BCVA). A positive change from baseline indicated improvement.

Time frame:
Baseline (BL), Month 1 through Month 6, Month 1 through Month 12
Reported as:
Mean · letters
Average Change From Baseline in BCVA
lettersRanibizumabSham Control
Average change from BL, month 1 through month 69.53 ± 10.4674.68 ± 8.786
Average change from BL, month 1 through month 129.99 ± 11.5286.59 ± 10.666
SecondaryNumber of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters
ParticipantsRanibizumabSham Control
Month 2,>=15 letters or reaching 84 let.(n=118,57)377
Month 2, >=10 letters (n=118,57)508
Month 2, >=5 letters (n=118,57)8316
Month 2, >=1 letter (118,57)10127
Month 6,>=15 letters or reaching 84 let.(n=118,54)5320
Month 6, >=10 letters (n=118,54)6724
Month 6, >= 5 letters (n=118,54)8834
Month 6, >= 1 letter (n=118,54)10439
Month 12,>=15 letters or reaching 84 let.;n=113,555523
Month 12, >=10 letters (n=113,55)6428
Month 12, >=5 letters (n=113,55)8134
Month 12, >=1 letter (n=113,55)10042
SecondaryNumber of Participants With > 1, > 5, > 10 and > 15 Letters Loss

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss
ParticipantsRanibizumabSham Control
Month 2, loss of >1 letter (n=118,57)1024
Month 2, loss of >5 letters (n=118,57)312
Month 2, loss of >10 letters (n=118,57)15
Month 2, loss of >15 letters (n=118,57)13
Month 6, loss of >1 letter (n=118,54)109
Month 6, loss of >5 letters (n=118,54)75
Month 6, loss of >10 letters (n=118,54)62
Month 6, loss of >15 letters (n=118,54)32
Month 12, loss of >1 letter (n=113,55)910
Month 12, loss of >5 letters (n=113,55)66
Month 12, loss of >10 letters (n=113,55)54
Month 12,loss of >15 letters (n=113,55)32
SecondaryNumber of Participants With Requirement for Rescue Treatment at Month 1

Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.

Time frame:
Month 1
Reported as:
Number · Participants
Number of Participants With Requirement for Rescue Treatment at Month 1
ParticipantsRanibizumabSham Control
Number of Participants With Requirement for Rescue Treatment at Month 101
SecondaryNumber of Participants With Ranibizumab Treatments in Study Eye

The number of participants administered study treatments, according to treatment frequency, was assessed.

Time frame:
Month 12
Reported as:
Number · Participants
Number of Participants With Ranibizumab Treatments in Study Eye
ParticipantsRanibizumabSham ControlSham Without Ranibizumab
Frequency of injections = 0007
Frequency of injections = 11250
Frequency of injections = 21260
Frequency of injections = 31970
Frequency of injections = 41360
Frequency of injections = 5950
Frequency of injections = 61160
Frequency of injections = 7220
Frequency of injections = 8810
Frequency of injections = 9540
Frequency of injections = 107100
Frequency of injections = 11600
Frequency of injections = 121500
SecondaryNumber of Participants With Re-treatments

The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to month 12, the maximum number of retreatments was 5.

Time frame:
Month 12
Reported as:
Number · Paticipants
Number of Participants With Re-treatments
PaticipantsRanibizumabSham ControlSham Without Ranibizumab
Frequency of re-treatment = 125210
Frequency of re-treatment = 222100
Frequency of re-treatment = 3940
Frequency of re-treatment = 4520
SecondaryNumber of Primary Reasons for Decision to Treat by Investigator

The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.

Time frame:
Month 12
Reported as:
Number · Number of primary reasons
Number of Primary Reasons for Decision to Treat by Investigator
Number of primary reasonsRanibizumabSham ControlSham Without Ranibizumab
Vision impairment2990
OCT abnormality5223061
FA abnormality21130
Color fundus photography abnormality100
Clinical abnormality600
Without documentation100

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab—9/119 (7.6%)42/119 (35.3%)
Sham With Ranibizumab—4/52 (7.7%)19/52 (36.5%)
Sham Without Ranibizumab—0/7 (0%)4/7 (57.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRanibizumabSham With RanibizumabSham Without Ranibizumab
FaecalomaGastrointestinal disorders0/1191/520/7
PyrexiaGeneral disorders0/1191/520/7
UrosepsisInfections and infestations0/1191/520/7
Rheumatic disorderMusculoskeletal and connective tissue disorders0/1191/520/7
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/520/7
OliguriaRenal and urinary disorders0/1191/520/7
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1191/520/7
Atrial fibrillationCardiac disorders1/1190/520/7
Retinal detachment (Fellow untreated eye)Eye disorders1/1190/520/7
Abdominal pain upperGastrointestinal disorders1/1190/520/7
Most frequent other events
Showing 10 of 16
Most frequent other events
EventRanibizumabSham With RanibizumabSham Without Ranibizumab
NasopharyngitisInfections and infestations14/1199/521/7
Choroidal neovascularisation (Study eye)Eye disorders3/1190/521/7
Eye inflammation (Study eye)Eye disorders0/1190/521/7
Foreign body sensation in eyes (Study eye)Eye disorders1/1191/521/7
Macular oedema (Study eye)Eye disorders0/1190/521/7
Ocular hyperaemia (Study eye)Eye disorders1/1191/521/7
Photopsia (Study eye)Eye disorders1/1190/521/7
Visual acuity reduced (Study eye)Eye disorders3/1191/521/7
PneumoniaInfections and infestations1/1190/521/7
Back painMusculoskeletal and connective tissue disorders6/1190/521/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RanibizumabSham ControlTotal
Mean54.6 ± 15.0751.9 ± 17.2953.7 ± 15.85
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabSham ControlTotal
Female603090
Male592988
08

Study locations

59 sites
  • Novartis Investigative Site
    Sydney, New South Wales 2000, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    South Launceston, Tasmania 7249, Australia
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Hradec Kralove, 505 05, Czech Republic
  • Novartis Investigative Site
    Praha 10, 100 34, Czech Republic
  • Novartis Investigative Site
    Glostrup, 2600, Denmark
  • Novartis Investigative Site
    Paris cedex 10, 75010, France
  • Novartis Investigative Site
    Paris, Cedex 12, F-75571, France
  • Novartis Investigative Site
    Bochum, 44892, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Freiburg i. Br, 79106, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Heraklion Crete, GR 711 10, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 56429, Greece
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Debrecen, 4043, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Roma, RM 00198, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Varese, VA 21100, Italy
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 06591, Korea, Republic of
  • Novartis Investigative Site
    Busan, 602-739, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 150-034, Korea, Republic of
  • Novartis Investigative Site
    Riga, 1002, Latvia
  • Novartis Investigative Site
    Kaunas, LTU 50009, Lithuania
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    San Isidro, Lima 27, Peru
  • Novartis Investigative Site
    Katowice, 40-594, Poland
  • Novartis Investigative Site
    Wroclaw, 50-556, Poland
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Porto, 4200-319, Portugal
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 119021, Russian Federation
  • Novartis Investigative Site
    Moscow, 127486, Russian Federation
  • Novartis Investigative Site
    Singapore, 168751, Singapore
  • Novartis Investigative Site
    Banska Bystrica, 97517, Slovakia
  • Novartis Investigative Site
    Trencin, 91171, Slovakia
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Sant Cugat, Catalunya 08190, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Binningen, 4102, Switzerland
  • Novartis Investigative Site
    Lausanne, 1007, Switzerland
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Istanbul, 34420, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2013
First posted
Apr 25, 2013
Start
Sep 2013
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Aug 26, 2016
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01840410
Responsible party
Sponsor
First posted
Apr 25, 2013
Start date
Sep 2013
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Aug 26, 2016
Last update
Aug 26, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion